Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes

被引:83
作者
Grünebach, F [1 ]
Müller, MR [1 ]
Nencioni, A [1 ]
Brossart, P [1 ]
机构
[1] Univ Tubingen, Dept Hematol Oncol & Immunol, D-72076 Tubingen, Germany
关键词
dendritic cells; RNA transfection; CTL; immunotherapy;
D O I
10.1038/sj.gt.3301901
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dendritic cells (DC) are professional antigen-presenting cells playing a central role in the induction of antigen-specific cytotoxic T-lymphocytes (CTL). We analyzed the efficiency of tumor RNA transfection into DC using different sources of RNA as well as delivery strategies including electroporation, lipofection and CD71-receptor-based delivery. To evaluate the sensitivity of these approaches, we utilized in vitro transcribed enhanced green fluorescence protein (EGFP)-RNA and whole tumor RNA from EGFP-transfected renal cell carcinoma cell line N43. We demonstrate that electroporation was the most effective way yielding about 30% EGFP positive cells while less than 1% of DC expressed EGFP using the transferrin receptor transfection system. Delivery of RNA with liposomes resulted in 17.5% of EGFP positive cells depending on the RNA amount. However, when these approaches were applied to transduce DC with RNA derived from the A498 cell line for T-cell priming, tumor-specific CTL could be induced using all delivery strategies suggesting that this technology has the potential to induce cytotoxic T-cell response even when low level of antigen is delivered. Furthermore, we demonstrate that amplification of whole tumor messenger RNA (mRNA) as well as the use of total instead of purified mRNA can be utilized for stimulating tumor-specific CTL responses.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 34 条
[1]  
BAKKER ABH, 1995, CANCER RES, V55, P5330
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]  
Boczkowski D, 2000, CANCER RES, V60, P1028
[4]   Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo [J].
Boczkowski, D ;
Nair, SK ;
Snyder, D ;
Gilboa, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :465-472
[5]  
Brossart P, 1998, CANCER RES, V58, P732
[6]   Dendritic cells in cancer vaccines [J].
Brossart, P ;
Wirths, S ;
Brugger, W ;
Kanz, L .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (11) :1247-1255
[7]   Presentation of exogenous protein antigens on major histocompatability complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines [J].
Brossart, P ;
Bevan, MJ .
BLOOD, 1997, 90 (04) :1594-1599
[8]   Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor [J].
Brossart, P ;
Grünebach, F ;
Stuhler, G ;
Reichardt, VL ;
Möhle, R ;
Kanz, L ;
Brugger, WR .
BLOOD, 1998, 92 (11) :4238-4247
[9]  
Brossart P, 1997, J IMMUNOL, V158, P3270
[10]  
Bubeník J, 2001, INT J ONCOL, V18, P475